A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea

참고문헌 (8)

1. Bain BJ, "Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?", Br J Haematol, 166, pp.809~817 (2014)
2. Patterer V, "Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1", Ann Hematol, 92, pp.759~769 (2013)
3. Saba N, "A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene", Blood, 122, pp.861~ (2013)
4. Bousquet M, "The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene", Oncogene, 24, pp.7248~7252 (2005)
5. Reiter A, "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2", Cancer Res, 65, pp.2662~2667 (2005)
6. Schwaab J, "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes", Ann Hematol, 94, pp.233~238 (2015)
7. Hoeller S, "PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms", Expert Opin Ther Targets, 15, pp.53~62 (2011)
8. Pileri SA, "Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients", Leukemia, 21, pp.340~350 (2007)

관련 논문AI추천